Novo Nordisk’s oral GLP-1 drug didn’t work on Alzheimer’s as hoped, but don’t call ...

Novo Nordisk’s stock tumbles after its oral GLP-1 drug didn’t show a statistically significant benefit over a placebo against ...
Zacks Investment Research on MSN

Will NVO's U.S. Price Cuts Boost Access & Revive Semaglutide Demand?

Last week, Novo Nordisk NVO announced that its popular semaglutide-based GLP-1 injections, Wegovy (for obesity) and Ozempic ...

Ocular Therapeutix, Inc.: Ocular Therapeutix Announces First Patient Randomized in HELIOS-3 ...

First patient randomized into HELIOS-3, which along with HELIOS-2 form the basis of AXPAXLI's registrational program in non-proliferative diabetic retinopathy (NPDR) HELIOS-2 and HELIOS-3 are global ...

Research reveals 4p tea could 'mimic' weight loss medication

A common hot beverage costing a mere 4p could "mimic" the effects of weight loss medication, suggests recent findings.